How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Prevention and treatment of cardiac hypertrophy with wogonin (P - 933)

Organization name

DKFZ Deutsches Krebsforschungszentrum

Profile

Background

In recent years, many efforts have been made to find compounds for the treatment of cardiac diseases. Traditional approaches to the suppression of cardiac hypertrophy have focused on outsidein signaling, e.g. to block neurohormones or calcium triggers. However, these treatments vary in effectiveness. Wogonin is the active component of extracts of the herbal remedy Scutellaria baicalensis, which is used intraditional Chinese medicine for the treatment of diseases such ashyperlipidemia, atherosclerosis, hypertension, dysentery, common cold and atopic dermatitis. Wogonin shows low toxicity in different animal models.

The Technology

Cardiac hypertrophy is characterized by a globalincrease in transcription and protein per cell. Cyclin-dependent kinase 9 (CDK9) is the maindriver for transcription and is necessary for hypertrophy in cardiomyocytes (Sano et al., 2002, 2004; Kulkarni et al., 2004). DKFZ scientists have shown that wogoninis a potent inhibitor of CDK9 with no, or very low, toxicity to normal tissues (Polier et al., 2011; Talbiet al., 2014). Wogonin can be used for preventing cardiac hypertrophy.

Advantages

  • Cardiac hypertrophy is a serious medical problem for many people in various countries
  • Wogonin reduces at least one or more symptoms of cardiac hypertrophy
  • Wogonin can be used to prevent cardiac hypertrophy and its associated symptoms

Development Stage

In-vitro verified technology. Preliminary clinical experiments are ongoing.

Applications and Commercial Opportunity

Wogonin can be isolated from the roots of Scutellaria baicalensisor prepared by chemical synthesis. Wogonin also shows anticancer activities in various tumor cells. DKFZ is seeking a commercial partner interested in this promising new application.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries